Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0047u-genomic-prostate-score-gps-test
    Ask Trek AI about this page

    CPT 0047U: Genomic Prostate Score (GPS) Test, RT-PCR mRNA Profiling

    CPT code 0047U is a Proprietary Laboratory Analyses (PLA) code for the Genomic Prostate Score® (GPS) Test from MDxHealth Inc., a laboratory assay that uses real-time polymerase chain reaction (RT–PCR) to perform mRNA gene expression profiling of 17 genes combined with patient data in an algorithm to predict mortality risk or estimate postprostatectomy recurrence risk; service type: laboratory molecular diagnostic test; typical site of service: hospital or independent clinical laboratory (clinical lab performing specialized molecular testing).

    For related coverage guidance, see recent payer policy updates: RTM Testing of Homocysteine Metabolism-Related Conditions, Multimarker Serum Testing Related to Ovarian Cancer, Genomic Profiling for Selecting Targeted Cancer Therapies.

    Customize your policy alerts

    Sign up for cpt 0047U policy alerts

    Get alerted when payer policies referencing 0047U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is a man diagnosed with clinically localized prostate cancer or an elevated prostate‑specific antigen (PSA) with biopsy-proven prostate adenocarcinoma who and his treating urologist or oncologist is evaluating individualized postoperative or treatment decision-making. The Genomic Prostate Score® (GPS) Test 0047U is ordered after diagnostic prostate needle biopsy or at time of prostatectomy tissue availability to assess mRNA expression of 17 genes by real‑time PCR and integrate results with clinical features. The workflow: the clinician obtains informed consent, submits formalin‑fixed paraffin‑embedded (FFPE) biopsy or prostatectomy tissue and relevant clinical data to the testing laboratory; the lab performs RNA extraction, RT‑PCR expression profiling and applies the proprietary algorithm to generate a GPS result; the laboratory reports the score to the ordering provider, who uses the score alongside PSA, Gleason grade group, tumor stage and patient preferences to inform prognosis and decisions about active surveillance, definitive therapy intensification, or adjuvant treatment consideration. Typical site of service is an independent or hospital-based clinical molecular pathology laboratory performing the high-complexity molecular test; specimen collection occurs in an ambulatory surgery center, outpatient clinic, or hospital operating room for biopsy or prostatectomy, with the laboratory component reported using 0047U.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    88305Level IV surgical pathology, gross and microscopic examinationOften performed on prostate biopsy or radical prostatectomy specimens before or concurrently with molecular testing to establish histologic diagnosis and provide tumor content assessment required for GPS testing.
    88172Cytopathology, cell block specimen, preparationMay be used if specimen processing requires cell block preparation prior to molecular analysis (occasionally applicable for limited tissue scenarios).
    81479Unlisted molecular pathology procedureHistorically used for novel molecular tests prior to PLA assignment; replaced by PLA 0047U for this specific GPS test but may appear in legacy workflows.
    88342Immunohistochemistry for single or multiple antigens (per slide)Used in tumor characterization and to help determine eligibility or adequacy of tissue for molecular profiling.
    84999Unlisted chemistry procedureRare; may be used in ancillary laboratory billing for nonstandard sample preparation or ancillary testing related to sample quality control.
    99000Handling and/or conveyance of specimen for transfer to another labUsed when specimens are transported to an external reference laboratory performing 0047U testing; documents specimen handling logistics and may be required by some billing systems.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…

    Related Provider Taxonomies

    8 rows

    Taxonomy CodeSpecialtyNotes
    2080P0208XPediatric Infectious Diseases PhysicianA pediatrician trained to care for children in the diagnosis, treatment and prevention of infectious diseases. This specialist can apply specific know…
    207L00000XAnesthesiology PhysicianAn anesthesiologist is trained to provide pain relief and maintenance, or restoration, of a stable condition during and immediately following an opera…
    2084P0800XPsychiatry PhysicianA Psychiatrist specializes in the prevention, diagnosis, and treatment of mental disorders, emotional disorders, psychotic disorders, mood disorders, …
    363A00000XPhysician AssistantA physician assistant is a person who has successfully completed an accredited education program for physician assistant, is licensed by the state and…
    207K00000XAllergy & Immunology PhysicianAn allergist-immunologist is trained in evaluation, physical and laboratory diagnosis, and management of disorders involving the immune system. Select…
    207SC0300XClinical Cytogenetics PhysicianA clinical cytogeneticist demonstrates competence in providing laboratory diagnostic and clinical interpretive services dealing with cellular componen…
    363LA2100XAcute Care Nurse PractitionerPhysician Assistants & Advanced Practice Nursing Providers · Nurse Practitioner
    2471C1101XCardiovascular-Interventional Technology Radiologic TechnologistA radiologic technologist who specializes in cardiovascular interventional technology.

    Related ICD-10-CM Codes

    25 rows

    ICD-10-CM CodeDescription
    C61Malignant neoplasm of prostate
    D07.5Carcinoma in situ of prostate
    D29.1Benign neoplasm of prostate
    D40.0Neoplasm of uncertain behavior of prostate
    D41.4Neoplasm of uncertain behavior of bladder
    N40.0Benign prostatic hyperplasia without lower urinary tract symptoms
    N40.1Benign prostatic hyperplasia with lower urinary tract symptoms
    N40.2Nodular prostate without lower urinary tract symptoms
    N40.3Nodular prostate with lower urinary tract symptoms
    N41.0Acute prostatitis

    Showing 1–10 of 25

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    RTM Testing of Homocysteine Metabolism-Related ConditionsOscar Health2026-10-01
    Multimarker Serum Testing Related to Ovarian CancerBlue Cross Blue Shield - Rhode Island2026-09-01
    Genomic Profiling for Selecting Targeted Cancer TherapiesBlue Cross Blue Shield - Rhode Island2026-09-01
    Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic DisordersBlue Cross Blue Shield - Rhode Island2026-09-01
    Biomarker and Genetic/Molecular Testing Coverage and Prior AuthorizationBlue Cross Blue Shield - Rhode Island2026-09-01
    Non-Invasive Prenatal Testing (NIPT)univerahealthcare2026-08-17
    Lumizyme (alglucosidase alfa) — Pompe Disease (acid alpha‑glucosidase deficiency)Cigna2026-08-15
    Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment DecisionsColorado Rocky Mountain Health Plans2026-08-01
    Carrier Testing Panels for Genetic DiseasesColorado Rocky Mountain Health Plans2026-08-01
    Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment DecisionsColorado Rocky Mountain Health Plans2026-08-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.